Roth Capital Starts Biotie Therapies (BITI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Roth Capital Starts Biotie Therapies (BITI) at Buy
July 6, 2015 8:02 AM EDT
JMP Securities initiated coverage on Biotie Therapies (NASDAQ: BITI) with a Market Outperform rating and a price target of $32.00.
For an analyst ratings summary and ratings history on Biotie Therapies click here. For more ratings news on Biotie Therapies click here.
Shares of Biotie Therapies closed at $18.39 yesterday.
...
More
July 6, 2015 8:01 AM EDT
Stifel initiated coverage on Biotie Therapies (NASDAQ: BITI) with a Buy rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Biotie Therapies click here. For more ratings news on Biotie Therapies click here.
Shares of Biotie Therapies closed at $18.39 yesterday.
...
More
July 6, 2015 8:01 AM EDT
(Updated - July 6, 2015 8:29 AM EDT)
RBC Capital initiated coverage on Biotie Therapies (NASDAQ: BITI) with an Outperform rating and a price target of $35. Analyst Simos Simeonidis is bullish on Tozadenant and thinks it could be the first Parkinsons Disease drug approved with a new mechanism in a generation.
"Tozadenant, Biotie's A2A receptor antagonist, is entering a Phase III... More
